Clinical Trial Update: Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer is ongoing, with status currently unk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Taizhou Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN